A novel cancer therapy to stimulate oncogenic ERK signalling

Obtenir text complet
Series

Current challenges in the design of antibody-drug conjugates

Obtenir text complet
Series

Antiviral drugs (non-HIV)

Obtenir text complet
Series

Complement as a therapeutic target

Obtenir text complet
Series (Complement system)
Series (Macular degeneration)

Animal models of seizures and epilepsy

Obtenir text complet
Series (Animal models in biomedical research)
Series (Epilepsy and seizures)

Receptor-channel research at the interface between academia and pharma

Obtenir text complet
Obtenir text complet
Series (Synapses, neurotransmitters and receptor channels)

Overview of clinical pharmacology in cancer part 1 of 2 /

Obtenir text complet
Series

Arylamine N-acetyltransferases part 2 of 3 /

Obtenir text complet
Series

Arylamine N-acetyltransferases part 3 of 3 /

Obtenir text complet
Series

Cytochrome P450 1 family the roles of 1A1, 1A2 and 1B1 in drug metabolism /

Obtenir text complet
Series

Arylamine N-acetyltransferases part 1 of 3 /

Obtenir text complet
Series

A systems biology approach to drug development clinical testing of biomarkers for the anti-ErbB3 antibody MM-121 /

Obtenir text complet
Series

Pharmacometrics in psychiatry

Obtenir text complet

The challenge of developing drugs for neglected parasitic diseases

Obtenir text complet
Series

Tuberculosis new treatments in evolution /

Obtenir text complet
Series

Key drug discovery challenges in cardiovascular medicine

Obtenir text complet
Series (Genetics of cardiovascular disease)
Series (Small molecule drug discovery)

Immune response and rational development of vaccines and biomarkers

Obtenir text complet
Series

Global progress in TB vaccine development

Obtenir text complet
Series

The future of influenza vaccines

Obtenir text complet
Series

Disease-modifying therapies for Parkinson's disease

Obtenir text complet
Series